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See Article, pages 883–889In 2009, a now seminal genome wide association study led to the
discovery of a nucleotide polymorphism, rs12979860, upstream
of the interleukin 28B (IL28B) gene. The CC IL28B genotype was
associated with an over twofold improvement in response to
treatment with pegylated interferon and ribavirin (PR) in patients
with genotype 1 chronic hepatitis C virus (HCV) infection [1]. In
an intention-to-treat analysis evaluating on-treatment virologic
response and sustained virologic response (SVR) in a large cohort
of genotype 1 HCV infected patients, the CC IL28B genotype was
associated with an improved SVR in Caucasians of 69% as com-
pared to 33% for the CT and 27% for the TT genotypes. These ﬁnd-
ings were similar across other ethnic groups. The CC IL28B
genotype was the strongest pretreatment predictor of SVR. Rapid
virologic response (RVR) was a strong predictor of SVR regardless
of IL28B genotype, and in non-RVR patients, the CC IL28B geno-
type was associated with a higher rate of SVR [2]. Given the lack
of alternative therapies, the multiple side effects of dual therapy,
and the prolonged course of treatment with overall low rates of
cure, IL28B testing held promise as a prime example of applying
pharmacogenomics to the planning of antiviral therapy. How-
ever, the discovery came at a time when HCV treatment was
undergoing signiﬁcant evolution with the development of direct
acting antiviral (DAA) agents.
In 2011, the ﬁrst generation HCV protease inhibitors, telapre-
vir, and boceprevir, were approved in combination with PR for
genotype 1 HCV infection. With a nearly twofold increase in
SVR compared to PR alone, the utility of IL28B genotyping could
be called into question. Would the improved outcome for all
comers accompanying telaprevir and boceprevir effectively nul-
lify the predictive value of IL28B genotype? Or, could IL28B geno-
typing be used to determine which patients should succeed
equally well receiving standard dual therapy versus triple ther-
apy, especially given the cost of the DAAs? Could IL28B genotyp-
ing identify those patients who could receive an abbreviated
course of therapy or could this question be answered with on-
treatment virologic milestones alone? While IL28B genotyping
was not available during the prospective randomized trials forJournal of Hepatology 20
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In a retrospective analysis of those patients who consented to
genetic testing in two large boceprevir trials for treatment naïve
(SPRINT-2 [3]) and treatment experienced (RESPOND-2 [4])
patients, the main role for IL28B genotyping was in the prediction
of those patients who could receive a shorter duration of therapy
in the response guided therapy groups. In the SPRINT-2 trial, in
which patients were randomized to 4 weeks of PR lead-in fol-
lowed by 44 weeks of boceprevir and PR, a response guided ther-
apy group, in which all patients received a 4 week PR lead-in and
then boceprevir and PR for an additional 24 weeks, with an addi-
tional 20 weeks of PR if the viral load was detectable between
weeks 8 and 24, or 48 weeks of PR alone, SVR rates for the favor-
able IL28B CC patients were high regardless of treatment arm
(78% for PR alone, 82% for boceprevir response guided therapy
group, and 80% for boceprevir/PR 48 week group). IL28B genotype
was independently associated with the outcome of boceprevir
based therapy. When interferon responsiveness, deﬁned as a
P1 log10 decline in HCV viral load at week 4 was added to the
multivariable logistic regression model, IL28B genotype was no
longer a signiﬁcant predictor of SVR, indicating that on-treatment
viral kinetics are the functional equivalent of IL28B genotype. Low
baseline viral load, absence or cirrhosis, HCV subtype 1b, and
lower BMI did remain signiﬁcant predictors of SVR. For previ-
ously treated patients, IL28B genotype was not a signiﬁcant pre-
dictor of overall SVR; only aP1 log10 decline in week 4 HCV viral
load and prior response category, previous relapse versus previ-
ous non-response, were signiﬁcant. Again, more patients in the
CC category were eligible for a shortened duration of therapy [5].
There had been more limited data for the role of IL28B geno-
typing in patients receiving telaprevir. IL28B in telaprevir treat-
ment naïve patients was evaluated retrospectively in 42% of
patients in the ADVANCE [6] study population. Only Caucasians
were included in this analysis. Since genotyping was performed
in de-identiﬁed specimens, no formal statistical analysis was per-
formed and other clinical and demographic data such as viral
load and ﬁbrosis stage were not evaluated. Rates of SVR in the
telaprevir group were higher than in the PR group among all
patients (CC and non-CC). Again, the presence of the IL28B CC
genotype identiﬁed patients who were eligible for a shortened
duration of therapy (those that achieved extended RVR (eRVR)
as deﬁned by undetectable HCV RNA at weeks 4 and 12). How-
ever, as with boceprevir, on-treatment viral kinetics were the13 vol. 58 j 847–849
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main predictor of SVR, since SVR rates were excellent in all
patients who achieved eRVR regardless of IL28B genotype. Ninety
one percent of those telaprevir-treated eRVR patients achieved
SVR (97% CC, 88% non-CC) with 24 weeks of therapy, whereas
only 45% of non-eRVR telaprevir patients had SVR with 48 weeks
of therapy. Among non-EVR patients, IL28B testing had more util-
ity, as SVR was higher in CC (67%) as compared to non-CC (38%)
patients [7]. In a sub analysis of the PROVE2 trial [8] in which
non-cirrhotic treatment naïve HCV genotype 1 patients were ran-
domized to 12 weeks of telaprevir and PR, 12 weeks of telaprevir,
PR and an additional 12 weeks of PR, 12 weeks of telaprevir and
PegIFN alone, or 48 weeks of PR, 100% (12/12) of the genotype
CC patients achieved an SVR with only 12 weeks of telaprevir
and PR [9], suggesting that patients with IL28B CC genotype
may be eligible for an even shorter course of therapy than
described in the ADVANCE trial.
In their sub analysis of the REALIZE study, Pol et al. provide us
with the missing piece of the puzzle on the role of IL28B testing in
the current era of triple therapy. They evaluated the impact of
IL28B genotype on SVR in telaprevir-treated HCV genotype 1
infected patients who had previously failed treatment with PR,
including null responders. In the REALIZE study, 662 patients
were randomized to 12 weeks of telaprevir with or without a
4 week PR lead in or placebo, each with PegIFN-a-2a and ribavi-
rin for 48 weeks overall [10]. Eighty percent of the subjects con-
sented to genetic testing and were included in this retrospective
analysis. Since the original trial showed no signiﬁcant difference
between the two telaprevir arms, these groups were pooled for
this study. SVR rates were higher in patients who received tela-
previr vs. placebo for all IL28B genotypes, CC 79% vs. 29%, CT
60% vs. 16% and TT 61% vs. 13%. SVR rates were similar irrespec-
tive of IL28B genotype for prior relapsers and prior partial
responders. For prior null responders, SVR rates were slightly
higher for the IL28B CC genotype than for non-CCs. In multivari-
able modeling, IL28B genotype did not signiﬁcantly affect SVR.
Prior response category, did however signiﬁcantly affect SVR
[11]. Thus, from this informative analysis, we can conclude that
there is a limited utility for IL28B testing in treatment experi-
enced patients being considered for telaprevir therapy, especially
those patients who have well deﬁned prior treatment courses.
Taken together, the results of the retrospective analyses of the
REALIZE, ADVANCE, SPRINT-2, RESPOND-2, and PROVE2 trials
indicate a limited role for IL28B genotyping. For treatment naïve
patients, the role of genotyping would appear to be limited to
encouraging those patients contemplating triple therapy to
undertake treatment because they would have a high likelihood
of requiring an abbreviated course of therapy. Interestingly, cost
effectiveness modeling studies have suggested that for those with
the CC genotype, dual PR therapy may be more cost effective
[12,13]. This, however, depends on the cost of the DAAs. For
treatment experienced patients whose prior treatment courses
have been well deﬁned in terms of quantitative HCV reduction,
there is no clear role for IL28B genotyping, since their interferon
responsiveness has already been deﬁned. IL28B genotyping may
be more helpful in counseling those patients whose prior treat-
ment courses have not been well deﬁned. Overall, though, on-
treatment kinetics will still be the most valuable predictor of
response in addition to other known clinical variables, such as
absence of cirrhosis and pretreatment viral load.
While these analyses are useful in clarifying the role for IL28B
in triple therapy, as we enter 2013, they are about to again be848 Journal of Hepatology 201supplanted by all oral interferon-free DAA regimens. What role
will there be for IL28B genotyping in the era of interferon-free
regimens? This question has been studied prospectively. In the
SOUND-C2 study, the efﬁcacy and safety of interferon-free com-
bination regimens of faldaprevir, an NS3/4A protease inhibitor
and BI207127, a non-nucleoside NS5B polymerase inhibitor, with
or without ribavirin in 362 genotype 1 HCV treatment-naïve
patients were evaluated. Of interest, IL28B genotype, genotype
1 subtype, and gender were identiﬁed as signiﬁcant baseline pre-
dictors of SVR. The difference in response to therapy according to
IL28B subtype was conﬁned primarily to 1a, since 1b patients did
uniformly well [14]. The ﬁnding of a predictive value for IL28B
genotype indirectly suggests the contribution of the host innate
immune response even to an IFN-sparing all-DAA regimen.
Recently Poordad et al., evaluated ABT-450, an NS3 protease
inhibitor, boosted with low-dose ritonavir, plus ABT-333, a non-
nucleoside NS5B polymerase inhibitor, and ribavirin in genotype
1 HCV infected patients. For previously untreated patients, up to
95% of patients experienced an SVR 12 weeks after the end of
treatment, and all previously untreated patients with CT/TT
IL28B genotypes experienced SVR [15]. It was also recently shown
that the combination of ABT-450/ritonavir with ABT-333 and
another DAA, ABT-267, led to an SVR 12 weeks after therapy
completion in 93% (42/45) of previous null responders despite a
high frequency of the non-favorable IL28B non-CC genotype
[16]. In a study of the nucleotide polymerase inhibitor sofosbuvir
and ribavirin, 21/25 previously untreated patients with genotype
1 HCV achieved SVR 24 weeks after therapy. 11/25 patients were
genotype CC [17]. Thus, while there may be a role for IL28B geno-
typing in genotype 1a patients for some DAA combinations,
emerging data on regimens with very high SVR rates will likely
limit IL28B testing to difﬁcult-to-treat-patients or to justiﬁcation
of even more simpliﬁed regimens in uncomplicated patients. As
treatment options for HCV rapidly unfold, so too must our ability
to provide predictive tools that enable us to tailor therapy to the
individual patient.
Conﬂict of interest
The authors declared that they do not have anything to disclose
regarding funding or conﬂict of interest with respect to this
manuscript.
References
[1] Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic
variation in IL28B predicts hepatitis C treatment-induced viral clearance.
Nature 2009;461:399–401.
[2] Thompson AJ, Muir AJ, Sulkowski MS, Ge D, Fellay J, Shianna KV, et al.
Interleukin-28B polymorphism improves viral kinetics and is the strongest
pretreatment predictor of sustained virologic response in genotype 1
hepatitis C virus. Gastroenterology 2010;139:e118.
[3] Poordad F, McCone Jr J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al.
Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med
2011;364:1195–1206.
[4] Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzem S, et al.
Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J
Med 2011;364:1207–1217.
[5] Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS,
et al. Factors that predict response of patients with hepatitis C virus infection
to boceprevir. Gastroenterology 2012;143:608–618, e601–e605.
[6] Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR,
Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C
virus infection. N Engl J Med 2011;364:2405–2416.3 vol. 58 j 847–849
JOURNAL OF HEPATOLOGY
[7] Jacobson IM, Catlett I, Marcellin P, Bzowej NH, Muir AJ, Adda N, et al. 1369
Telaprevir substantially improved SVR rates across all IL28B genotypes in the
advance trial. J Hepatol 2011;54:S542–S543.
[8] Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, et al. Telaprevir
and peginterferon with or without ribavirin for chronic HCV infection. N Engl
J Med 2009;360:1839–1850.
[9] Bronowicki JP, Hezode C, Bengtsson L, Pol S, Bourliere M, Serfaty L, et al. 1094
100% SVR in IL28B CC patients treated with 12 weeks of telaprevir,
peginterferon and ribavirin in the PROVE2 trial. J Hepatol 2012;56:
S430–S431.
[10] Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, et al. Telaprevir
for retreatment of HCV infection. N Engl J Med 2011;364:2417–2428.
[11] Pol S, Aerssens J, Zeuzem S, Andreone P, Lawitz EJ, Roberts S, et al. Limited
impact of IL28B genotype on response rates in telaprevir-treated patients
with prior treatment failure. J Hepatol 2013;58:883–889.
[12] Liu S, Cipriano LE, Holodniy M, Owens DK, Goldhaber-Fiebert JD. New
protease inhibitors for the treatment of chronic hepatitis C. A cost-
effectiveness analysis. Ann Intern Med 2012;156:279–290.
[13] Gellad ZFNS, Reed SD, Clark PJ, Thompson AJ, Schulman KA, Muir AJ. The
cost-effectiveness of a telaprevir-inclusive regimen as initial therapy forJournal of Hepatology 201genotype 1 hepatitis C infection in individuals with the C/C IL28B polymor-
phism. Hepatology 2011;54:417A (118).
[14] Zeuzem S, Soriano V, Asselah T, Bronowicki J, Lohse A, Mullhaupt B, et al.
Interferon (IFN)-free combination treatment with the HCV NS3/4A protease
inhibitor BI 201335 and the non-nucleoside NS5B inhibitor BI 207127 ± riba-
virin (R): ﬁnal results of SOUND-C2 and predictors of response. AASLD
abstracts. Hepatology 2012;56:308A.
[15] Poordad F, Lawitz E, Kowdley KV, Cohen DE, Podsadecki T, Siggelkow S, et al.
Exploratory study of oral combination antiviral therapy for hepatitis C. N
Engl J Med 2013;368:45–53.
[16] Kowdley KV, Lawitz E, Poordad F, Cohen DE, Nelson DR, Zeuzem S, Everson
GT, et al. A 12-week interferon-free treatment regimen with ABT-450/r, ABT-
267, ABT-333 and ribavirin achieves SVR12 rates (observed data) of 99% in
treatment-naïve patients and 93% in prior null responders with HCV
genotype1 infection. Annual Meeting of the American Association for the
Study of Liver Diseases. 2012. Boston, MA, abstract LB-1.
[17] Gane EJ, Stedman CA, Hyland RH, Ding X, Svarovskaia E, Symonds WT, et al.
Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N
Engl J Med 2013;368:34–44.3 vol. 58 j 847–849 849
